Hostname: page-component-cd9895bd7-q99xh Total loading time: 0 Render date: 2024-12-23T14:57:25.609Z Has data issue: false hasContentIssue false
  • English
  • Français

Quetiapine for Mania Due to Traumatic Brain Injury

Published online by Cambridge University Press:  07 November 2014

Timothy J. Oster ,
C. Alan Anderson ,
Christopher M. Filley ,
Hal S. Wortzel  and
David B. Arciniegas
Get access Rights & Permissions [Opens in a new window]

Abstract

Secondary mania develops in as many as 9% of persons with traumatic brain injuries.The treatment of posttraumatic mania is not well defined, and agents traditionally used for the treatment of idiopathic manic episodes may not be well suited for use among individuals with traumatic brain injuries. Atypical antipsychotics are indicated for the treatment of idiopathic bipolar disorder, and have been used for other purposes among individuals with posttraumatic neuropsychiatric disturbances. This article offers the first description of the treatment of posttraumatic mania using the atypical antipsychotic quetiapine. Beneficial effects of this agent on posttraumatic mania, cognitive impairments, and functional disability in the subacute post-injury period are described. Possible mechanisms of action are discussed and the need for additional investigation of quetiapine for posttraumatic mania is highlighted.

Type
Case Report
Information
CNS Spectrums , Volume 12 , Issue 10 , October 2007 , pp. 764 - 769
Copyright
Copyright © Cambridge University Press 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Jorge, RE, Robinson, RG, Starkstein, SE, Arndt, SV, Forrester, AW, Geisler, FH. Secondary mania following traumatic brain injury. Am J Psychiatry. 1993;150:916–921.Google ScholarPubMed
2.van Reekum, R, Cohen, T, Wong, J. Can traumatic brain injury cause psychiatric disorders? J Neuropsychiatry Clin Neurosci. 2000;12:316–327.CrossRefGoogle Scholar
3.Jorge, R, Robinson, RG. Mood disorders following traumatic brain injury. Int Rev Psychiatry. 2003;15:317–327.CrossRefGoogle ScholarPubMed
4.Warden, DL, Gordon, B, McAllister, TW, et al.Guidelines for the pharmacologic treatment of neurobehavioral sequelae of traumatic brain injury. J Neurotrauma. 2006;23:1468–1501.CrossRefGoogle ScholarPubMed
5.Starkstein, SE, Pearlson, GD, Boston, J, Robinson, RG. Mania after brain injury. A controlled study of causative factors. Arch Neurol. 1987;44:1069–1073.CrossRefGoogle ScholarPubMed
6.Stewart, JT, Hemsath, RH. Bipolar illness following traumatic brain injury: treatment with lithium and carbamazepine. J Clin Psychiatry. 1988;49:74–75.Google ScholarPubMed
7.Bouvy, PF, van de Wetering, BJ, Meerwaldt, JD, Bruijn, JB. A case of organic brain syndrome following head injury sucessfully treated with carbamazepine. Acta Psychiatr Scand. 1988;77:361–363.CrossRefGoogle Scholar
8.Kim, E, Humaran, TJ. Divalproex in the management of neuropsychiatric complications of remote acquired brain injury. J Neuropsychiatry Clip Neurosci. 2002;14:202–205.CrossRefGoogle ScholarPubMed
9.Pope, HG, McElroy, SL, Satlin, A, Hudson, JI, Keck, PE Jr, Kalish, R. Head injury, bipolar disorder and response to valproate. Compr Psychiatry. 1988;29:34–38.CrossRefGoogle ScholarPubMed
10.Monji, A, Yoshida, I, Koga, H, Tashiro, K, Tashiro, N. Brain injury-induced rapid-cycling affective disorder successfully treated with valproate. Psychosomatics. 1999;40:448–449.CrossRefGoogle ScholarPubMed
11.Yassa, R, Cvejic, J. Valproate in the treatment of posttraumatic bipolar disorder in a psychogeriatric patient. J Geriatr Psychiatry Neurol. 1994;7:55–57.CrossRefGoogle Scholar
12.Mustafa, B, Evrim, O, Sari, A. Secondary mania following traumatic brain injury. J Neuropsychiatry Clin Neurosci. 2005;17:122–124.CrossRefGoogle ScholarPubMed
13.Murai, T, Fujimoto, S. Rapid cycling bipolar disorder after left temporal polar damage. Brain Inj. 2003;17:355–358.CrossRefGoogle ScholarPubMed
14.Arciniegas, DB, Topkoff, J, Silver, JM. Neuropsychiatric aspects of traumatic brain injury. Curr Treat Options Neurol. 2000;2:169–186.CrossRefGoogle ScholarPubMed
15.Arciniegas, DB, Harris, SN, Brousseau, KM. Psychosis following traumatic brain injury. Int Rev Psychiatry. 2003;15:328–340.CrossRefGoogle ScholarPubMed
16.Smith, KR Jr. Goulding, PM, Wilderman, D, Goldfader, PR, Holterman-Hommes, P, Wei, F. Neurobehavioral effects of phenytoin and carbamazepine in patients recovering from brain trauma: a comparative study. Arch Neurol. 1994;51:653–660.CrossRefGoogle ScholarPubMed
17.Hornstein, A, Seliger, G. Cognitive side effects of lithium in closed head injury. J Neuropsychiatry Clin Neurosci. 1989;1:446–447.CrossRefGoogle ScholarPubMed
18.Massagli, TL. Neurobehavioral effects of phenytoin, carbamazepine, and valproic acid: implications for use in traumatic brain injury. Arch Phys Med Rehabil. 1991;72:219–226.Google ScholarPubMed
19.Glenn, MB, Wroblewski, B, Parziale, J, Levine, L, Whyte, J, Rosenthal, M. Lithium carbonate for aggressive behavior or affective instability in ten brain-injured patients. Am J Phys Med Rehabil. 1989;68:221–226.CrossRefGoogle ScholarPubMed
20.Dikmen, SS, Machamer, JE, Winn, HR, Anderson, GD, Temkin, NR. Neuropsychological effects of valproate in traumatic brain injury: a randomized trial. Neurology. 2000;54:895–902.CrossRefGoogle ScholarPubMed
21.Temkin, NR, Dikmen, SS, Anderson, GD, et al.Valproate therapy for prevention of posttraumatic seizures: a randomized trial. J Neurosurg. 1999;91:593–600.CrossRefGoogle ScholarPubMed
22.Wilson, MS, Gibson, CJ, Hamm, RJ. Haloperidol, but not olanzapine, impairs cognitive performance after traumatic brain injury in rats. Am J Phys Med Rehabil. 2003;82:871–879.CrossRefGoogle Scholar
23.Rao, N, Jellinek, HM, Woolston, DC. Agitation in closed head injury: haloperidol effects on rehabilitation outcome. Arch Phys Med Rehabil. 1985;66:30–34.Google ScholarPubMed
24.Elovic, EP, Lansang, R, Li, Y, Ricker, JH. The use of atypical antipsychotics in traumatic brain injury. J Head Trauma Rehabil. 2003;18:177–195.CrossRefGoogle ScholarPubMed
25.Stanislav, SW. Cognitive effects of antipsychotic agents in persons with traumatic brain injury. Brain Inj. 1997;11:335–341.CrossRefGoogle ScholarPubMed
26.Kline, AE, Massucci, JL, Zafonte, RD, Dixon, CE, Defeo, JR, Rogers, EH. Differential effects of single versus multiple administrations of haloperidol and risperidone on functional outcome after experimental brain trauma. Crit Care Med. 2007;35:919–924.CrossRefGoogle ScholarPubMed
27.Bleiberg, J, Garmoe, W, Cederquist, J. Dexedrine on performance consistency following brain injury: a double-blind placebo crossover case study. Neuropsychiatry Neuropsych Behav Neurol. 1993;6:245–248.Google Scholar
28.Perlis, RH, Welge, JA, Vornik, LA, Hirsctifeld, RM, Keck, PE Jr. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry. 2006;67:509–516.CrossRefGoogle Scholar
29.Krieger, D, Hansen, K, McDermott, C, et al.Loxapine versus olanzapine in the treatment of delirium following traumatic brain injury. NeuroRehabilitation. 2003;18:205–208.CrossRefGoogle ScholarPubMed
30.Temple, MJ. Use of atypical anti-psychotics in the management of post-traumatic confusional states in traumatic brain injury. J R Army Med Corps. 2003;149:54–55.CrossRefGoogle ScholarPubMed
31.Bennouna, M, Greene, VB, Defranoux, L. Adjuvant galantamine to risperidone improves negative and cognitive symptoms in a patient presenting with schizophrenialike psychosis after traumatic brain injury. J Clin Psychopharmacol. 2005;25:505–507.CrossRefGoogle Scholar
32.Schreiber, S, Klag, E, Gross, Y, Segman, RH, Pick, CG. Beneficial effect of risperidone on sleep disturbance and psychosis following traumatic brain injury. Int Clin Psychopharmacol. 1998;13:273–275.CrossRefGoogle ScholarPubMed
33.Kim, E, Bijlani, M. A pilot study of quetiapine treatment of aggression due to traumatic brain injury. J Neuropsychiatry Clin Neurosci. 2006;18:547–549.CrossRefGoogle ScholarPubMed
34.Michals, ML, Crismon, ML, Roberts, S, Childs, A. Clozapine response and adverse effects in nine brain-injured patients. J Clin Psychopharmacol. 1993;13:198–203.CrossRefGoogle ScholarPubMed
35.Cole, P, Rabasseda, X. Quetiapine in bipolar disorder: increasing evidence of efficacy and tolerability. Drugs Today (Barc). 2004;40:837–852.CrossRefGoogle ScholarPubMed
36.Serretti, A, De, RD, Lorenzi, C, Berardi, D. New antipsychotics and schizophrenia: a review on efficacy and side effects. Curr Med Chem. 2004;11:343–358.CrossRefGoogle ScholarPubMed
37.Tandon, R, Jibson, MD. Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome. Ann Clin Psychiatry. 2002;14:123–129.CrossRefGoogle ScholarPubMed
38.Bilder, RM, Goldman, RS, Volavka, J, et al.Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry. 2002;159:1018–1028.CrossRefGoogle ScholarPubMed
39.Harvey, PD. Cognitive and functional effects of atypical antipsychotic medications. J Clin Psychiatry. 2006;67:e13.CrossRefGoogle ScholarPubMed
40.Harvey, PD, Bowie, CR, Loebel, A. Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a six-month randomized, double-blind comparison of ziprasidone vs. olanzapine. J Neuropsychiatry Clin Neurosci. 2006;18:54–63.CrossRefGoogle ScholarPubMed
41.Macqueen, G, Young, T. Cognitive effects of atypical antipsychotics: focus on bipolar spectrum disorders. Bipolar Disord. 2003;5:53–61.CrossRefGoogle ScholarPubMed
42.Folstein, MF, Folstein, SE, McHugh, PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–198.CrossRefGoogle ScholarPubMed
43.Dubois, B, Slachevsky, A, Litvan, I, Pillon, B. The FAB: a Frontal Assessment Battery at bedside. Neurology. 2000;55:1621–1626.CrossRefGoogle ScholarPubMed
44.Guide for the Uniform Data Set for Medical Rehabilitation (Including the FIMTM instrument), Version 5.1. Buffalo, NY: State University of New York at Buffalo; 1997.Google Scholar
45.Shukla, S, Cook, BL, Mukherjee, S, Godwin, C, Miller, MG. Mania following head trauma. Am J Psychiatry. 1987;144:93–96.Google ScholarPubMed
46.Starkstein, SE, Boston, JD, Robinson, RG. Mechanisms of mania after brain injury. 12 case reports and review of the literature. J Nerv Ment Dis. 1988;176:87–100.CrossRefGoogle ScholarPubMed
47.Starkstein, SE, Mayberg, HS, Berthier, ML, et al.Mania after brain injury: neuroradiological and metabolic findings. Ann Neurol. 1990;27:652–659.CrossRefGoogle ScholarPubMed
48.Vieta, E, Goikolea, JM. Atypical antipsychotics: newer options for mania and maintenance therapy. Bipolar Disord. 2005;7(suppl):21–33.CrossRefGoogle ScholarPubMed
49.Newman-Tancredi, A, Gavaudan, S, Conte, C, et al.Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. Eur J Pharmacol. 1998;355:245–256.CrossRefGoogle ScholarPubMed
50.Bymaster, FP, Falcone, JF, Bauzon, D, et al.Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine. Eur J Pharmacol. 2001;430:341–349.CrossRefGoogle Scholar
51.Tyson, PJ, Roberts, KH, Mortimer, AM. Are the cognitive effects of atypical antipsychotics influenced by their affinity to 5HT-2A receptors? Int J Neurosci. 2004;114:593–611.CrossRefGoogle ScholarPubMed
52.Yatham, LN, Goldstein, JM, Vieta, E, et al.Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry. 2005;66(suppl):40–48.Google ScholarPubMed
53.Buhot, MC, Martin, S, Segu, L. Role of serotonin in memory impairment. Ann Med. 2000;32:210–221.CrossRefGoogle ScholarPubMed
54.Ichikawa, J, Li, Z, Dai, J, Meltzer, HY. Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res. 2002;956:349–357.Google Scholar
55.Velligan, DI, Prihoda, TJ, Sui, D, Ritch, JL, Maples, N, Miller, AL. The effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings. J Clin Psychiatry. 2003;64:524–531.CrossRefGoogle ScholarPubMed
56.Randolph, C. RBANS Manual: Repeatable Battery for the Assessment of Neuropsychological Status. San Antonio, Tex: The Psychological Corporation (Harcourt); 1998.Google Scholar
57.Weickert, TW, Goldberg, TE, Marenco, S, Bigelow, LB, Egan, MF, Weinberger, DR. Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds. Neuropsychopharmacology. 2003;28:1491–1500.CrossRefGoogle Scholar
58.Yumru, M, Savas, HA, Kurt, E, et al.Atypical antipsychotics related metabolic syndrome in bipolar patients. J Affect Disord. 2006;98:247–252.CrossRefGoogle ScholarPubMed
59.Schneider, LS, Dagerman, KS, Insel, P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934–1943.CrossRefGoogle ScholarPubMed